Our research projects

Osteosarcoma bone cancer affects teenagers, around half of whom die within 5-years of diagnosis. We think we can solve these problems by modifying immune cells called “gamma-delta T-cells”.

Craniopharyngioma, a brain tumour affecting children, is difficult to treat. Work within the laboratories of the investigators has identified potential drugs that could turn off tumour growth. These drugs will be tested in patients whose tumours have regrown in a clinical trial.

Looking at the molecular effects inside Acute Myeloid Leukaemia cells treated with a specific new drug and investigating if the drug can be combined with other standard treatments.

Half of patients Ependymoma (EPN) with no disease after treatment on MRI relapse within 2 years. This suggests that they have low level or minimal residual disease (MRD). Developing an accurate MRD detection test could help improve survival.

Examining whether a group of drugs called gliflozins could be used to treat T-ALL

Developing and delivering small molecule drug and immunotherapy combinations for MYC-driven medulloblastoma: Efficacy, evolution and exploitation.

Single-cell transcriptomics linked to lineage tracing to interrogate the role of intra-tumour heterogeneity in shaping therapeutic susceptibility and resistance in paediatric cancer

Development of a multi-factorial prognostic model to optimise treatment decision making and outcomes in paediatric low-grade glioma

Defining the molecular landscape of paediatric and adolescent acute leukaemia in Tanzania